Skip to Main Content

Paper Details

Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With <i>METamp</i> After Osimertinib First-Line Treatment.
JCO Precis Oncol
0
2022
Author NameAffiliation
Dirce Maria CarraroInternational Research Center/CIPE, A.C. Camargo Cancer Center
Dirce Maria CarraroNational Institute of Science and Technology in Oncogenomics (INCITO)
  • 1 - 2

Datasets

Release 1.2